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Original Article
Objectives: Smoking is known to be associated with nephropathy in patients with diabetes. The distinct effects of smoking before 
and after diabetes has been diagnosed, however, are not well characterized. We evaluated the association of cigarette smoking before 
and after a diagnosis of diabetes with the presence of diabetic nephropathy.
Methods: We analyzed data from the 2011-2013 editions of the Korea National Health and Nutrition Examination Survey. A total of 
629 male patients diagnosed with diabetes were classified as non-smokers (90 patients), former smokers (225 patients), or continuing 
smokers (314 patients). A “former smoker” was a patient who smoked only before receiving his diagnosis of diabetes. A “continuing 
smoker” was a patient who smoked at any time after his diabetes had been diagnosed. Diabetic nephropathy was defined as the pres-
ence of albuminuria (spot urine albumin/creatinine ratio ≥30 mg/g) or low estimated glomerular filtration rate (<60 mL/min/1.73 
m2). Multiple logistic regression models were used to assess the independent association after adjusting for age, duration of diabetes, 
hemoglobin A1c, body mass index, systolic blood pressure, medication for hypertension, and medication for dyslipidemia. Female pa-
tients were excluded from the study due to the small proportion of females in the survey who smoked.
Results: Compared to non-smokers, continuing smokers had significantly higher odds ratio ([OR], 2.17;  95% confidence interval [CI], 
1.23 to 3.83) of suffering from diabetic nephropathy. The corresponding OR (95% CI) for former smokers was 1.26 (0.70 to 2.29).
Conclusions: Smoking after diagnosis of diabetes is significantly associated with the presence of diabetic nephropathy in the Korean 
male population.
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INTRODUCTION
Diabetic nephropathy is the leading cause of end-stage re-
nal disease and is also responsible for cardiovascular mortality 
[1-3]. About 30% of patients with diabetes eventually develop 
diabetic nephropathy [1,4]. In Korea, diabetic nephropathy is 
becoming a substantial health care problem as the number of 
patients with diabetes is continuously increasing [5,6].
Albuminuria and a decline in the glomerular filtration rate 
(GFR) are commonly used for early detection of diabetic ne-
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phropathy. Increased urinary albumin is the earliest clinical 
feature of diabetic nephropathy. Gradual declines in GFR fol-
low functional and structural changes of glomeruli [4,7].
Smoking has been reported to be associated with the pro-
gression of diabetic nephropathy. In prospective studies, pro-
gression to diabetic nephropathy was more frequent in smok-
ers than non-smokers [8-10]. These studies classified subjects 
as non-smokers, former smokers and current smokers and 
found the hazard highest for current smokers. These findings 
suggest that continued smoking is related to the development 
of diabetic nephropathy.
Many studies have also evaluated the association between 
smoking cessation and diabetic nephropathy. A recent decline 
in diabetes-related complications, including end-stage renal 
disease, was linked to management and improvement of risk 
factors including smoking cessation [11]. Other prospective 
studies have reported that smoking cessation slowed the pro-
gression of diabetic nephropathy [12,13].
Smoking has a known association with nephropathy in the 
non-diabetic population. Subjects classified as smokers at the 
time of study had a significantly higher prevalence of albumin-
uria and abnormal renal function [14,15]. Therefore, smoking, 
whether before or after being diagnosed with diabetes, might 
be expected to increase an individual’s risk of developing dia-
betic nephropathy. Previous studies, however, did not distin-
guish between the effect of smoking before and the effect of 
smoking after diagnosis. This study aims to make that distinc-
tion by considering the association between the presence of 
diabetic nephropathy and various smoking behaviors, specifi-
cally never smoking, smoking only before diagnosis, and smok-
ing at any point in time after receiving a diagnosis of diabetes. 
METHODS
We used data from the Korea National Health and Nutrition 
Examination Survey (KNHANES), a cross-sectional nationwide 
survey designed to assess the health and nutritional status of 
the Korean population [16]. The KNHANES selects a represen-
tative sample from the population and conducts personal in-
terviews, physical examinations, and clinical and laboratory 
tests. Because the measurement of urinary albumin was intro-
duced to the KNHANES in 2011, we used data from the 2011- 
2013 surveys. Females were excluded from our study because 
the reported prevalence of smoking among females in the 
survey was low. Moreover, research indicates that self-reports 
of smoking made by Asian females in similar surveys were un-
reliable [17]. Among the 9862 male participants during the 
three years, 708 subjects were reported to be diagnosed with 
diabetes by a physician. We excluded 79 subjects whose 
smoking status or other key variables were missing, leaving 
629 male patients with diabetes in our data set. The KNHANES 
data were publicly available for research, so separate ethical 
approval by our institutional review board was not required.
Participants were classified as non-smokers, former smokers 
and current smokers based upon a smoking history taken as 
part of the survey. Within the class “former smokers”, we esti-
mated the date of smoking cessation using details included in 
the smoking history. Questions pertaining to smoking cessa-
tion changed during our study period, so we applied different 
methods when estimating smoking cessation dates from dif-
ferent subsets of the survey data. With survey data from 2011 
to 2012, we added smoking duration to the age of smoking 
initiation. With data from 2013, we subtracted the duration of 
smoking cessation from current age. By comparing the age of 
smoking cessation and the age of diabetes diagnosis, we divid-
ed former smokers, as defined in the survey, into two groups. 
“Former smokers”, as we define them, were those who smoked 
before the diagnosis of diabetes, but never after. “Continuing 
smokers” were those who smoked at any time after diagnosis 
of diabetes. By this definition, we included those reported to 
be current smokers in the KNHANES in our class “continuing 
smokers”. Finally, KNHANES participants classified “non-smoker” 
were included in the class “non-smokers” in our study.
We adopted the definition and classification of chronic kid-
ney diseases recommended by the National Kidney Founda-
tion Kidney Disease Outcomes Quality Initiative to define dia-
betic nephropathy [18]. Diabetic nephropathy was defined as 
the presence of albuminuria or test results that show a low 
GFR. Presence of albuminuria was defined as a spot urine al-
bumin/creatinine ratio (ACR) ≥30 mg/g, including microalbu-
minuria (30 - 299 mg/g) and macroalbuminuria (≥300 mg/g). 
The Modification of Diet in Renal Disease formula was used to 
estimate the GFR: estimated GFR (mL/min/1.73 m2) =  186.3×
(serum creatinine)-1.154×(age)-0.203 × 0.742 (if female). Low GFR 
was defined to be estimated GFR <60 mL/min/1.73 m2.
We assessed known risk factors for diabetic nephropathy. 
They include age, duration of diabetes, hypertension, dyslipid-
emia, body mass index, systolic blood pressure, hemoglobin 
A1c (HbA1c), serum total cholesterol, and triglycerides. Dura-
tion of diabetes was calculated by taking the difference be-
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tween the year of diabetes diagnosis and current age. Medica-
tion for hypertension or for dyslipidemia was self-reported. 
Body mass index was calculated by dividing weight in kilo-
grams by squared height in meters. Because most of the par-
ticipants reported that they used anti-diabetic medications to 
treat their diabetes, we used HbA1c <7.0% as our indicator of 
adequate glycemic control. Dyslipidemia was defined as se-
rum total cholesterol ≥240 mg/dL, or serum triglyceride ≥
200 mg/dL, or taking medication for dyslipidemia.
To begin our analysis, we classified subjects by our criteria 
for diabetic nephropathy. The 416 subjects that did not meet 
our criteria were labeled “normal”. The 213 subjects that met 
our criteria were assigned the label “diabetic nephropathy”. We 
then compared characteristics of the two groups and the prev-
alence of risk factors in the two groups. We performed Stu-
dent’s t-tests when response values were continuous and chi-
square tests when values were categorical. Multiple logistic re-
gression analysis was used to investigate the independent as-
sociation between smoking before and after diagnosis of dia-
betes and the presence of diabetic nephropathy after adjust-
ing for age, duration of diabetes, body mass index, HbA1c, sys-
tolic blood pressure, medication for hypertension, and the 
presence of dyslipidemia. We separately analyzed the associa-
tion with each of our criteria for diabetic nephropathy: albu-
minuria and low GFR. In the analysis of albuminuria, a multino-
mial regression model was used. Albuminuria was subdivided 
into normoalbuminuria (ACR <30 mg/g), microalbuminuria 
(ACR=30-299 mg/g), and macroalbuminuria (ACR ≥300 mg/
g). GFR <60 mL/min/1.73 m2 was considered low. We repeated 
the analysis, regressing diabetic nephropathy against smoking 
history according to the life time smoking history (non-smok-
ers, former smokers, and current smokers) and further dividing 
life time former smokers by their smoking duration (<20 years 
and ≥20 years). The p-value <0.05 was  considered statistical-
ly significant. All statistical analyses were performed using SAS 
version 9.4 (SAS Institute Inc., Cary, NC, USA). 
RESULTS
The group of patients in our study, 629 male diagnosed with 
diabetes, is described by the basic characteristics recorded in 
Table 1. A large majority (85.7%) of patients smoked at some 
point in their lives. Among smokers, more than half (58.2%) 
continued smoking at some point after receiving their diagno-
sis of diabetes. Nearly 28% of all participants had albuminuria 
and slightly more than 12% had low GFR.
The overall prevalence of diabetic nephropathy was 33.9% 
(n=213) (Table 2). Compared to patients without diabetic ne-
phropathy, patients with diabetic nephropathy were signifi-
cantly older, had suffered diabetes for a longer period of time, 
had higher systolic blood pressure, were more likely to exhibit 
inadequate glycemic control, and were more likely to take 
medication for hypertension. Smoking behavior after diagno-
sis of diabetes was significantly different, with a higher pro-
portion of continuing smokers who smoked at any time after 
diagnosis of diabetes (56.8% vs. 46.4%; p=0.009) in the group 
of patients with diabetic nephropathy. There were no signifi-
cant differences in body mass index and the presence of dys-
lipidemia between the two groups.
We then made these comparisons in a different way, com-
paring these characteristics and risks across groups defined by 
each of the two criteria for diabetic nephropathy, albuminuria 
and low GFR. When grouped by albuminuria, there were signif-
icant differences in age, duration of diabetes, systolic blood 
pressure, HbA1c, medication for hypertension and smoking 
Table 1. Characteristics of 629 male patients with diabetes
Variables Male patients with diabetes
Age (y) 62.5±10.4
Diabetes duration (y) 9.1±8.5
Hemoglobin A1c (%) 7.44±1.42
Body mass index (kg/m2) 24.3±3.0
Systolic blood pressure (mmHg) 126.1±17.9
Smoking behavior
   Never smoked  90 (14.3)
   Smoked only before diagnosis of diabetes 225 (35.8)
   Ever smoked after diagnosis of diabetes 314 (49.9)
Medication for hypertension 
   No 321 (51.0)
   Yes 308 (49.0)
Dyslipidemia
   No 362 (57.5)
   Yes 267 (42.5)
Urine albumin/creatinine ratio (mg/g)
   <30 455 (72.3)
   ≥30 174 (27.7)
Glomerular filtration rate (mL/min/1.73 m2)1
   ≥60 551 (87.6)
   <60  78 (12.4)
Values are presented as mean±standard deviation or number (%).
1Glomerular filtration rate is estimated according to the Modification of Diet 
in Renal Disease formula.
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behavior after diagnosis of diabetes. When grouped by low 
GFR, there were significant differences in age, duration of dia-
betes, and medication for hypertension between the two 
groups.
Table 3 shows the association between smoking behavior 
after diagnosis of diabetes and the presence of diabetic ne-
phropathy. The unadjusted odds ratio (OR) and 95% confi-
dence intervals (CI) show that older age, longer duration of di-
abetes, higher systolic blood pressure, higher HbA1c, and tak-
ing medication for hypertension were significantly associated 
with the presence of diabetic nephropathy. After adjusting for 
all other variables, duration of diabetes and medication for hy-
pertension became insignificant. The unadjusted OR (95% CI) 
for former smokers who had smoked only before their diagno-
sis of diabetes was 1.29 (0.74 to 2.24), and the adjusted OR was 
1.23 (0.68 to 2.21). The unadjusted OR (95% CI) of continuing 
smokers who smoked at any time after diagnosis was 1.83 
(1.08 to 3.09). The OR remained significant after adjusting for 
all covariates (adjusted OR, 2.12; 95% CI, 1.20 to 3.73).
Table 4 shows the association of smoking behavior after a 
diagnosis of diabetes with selected levels of albuminuria and 
with low GFR. The adjusted OR (95% CI) of smoking at any 
time after diabetes diagnosis, relative to normoalbuminuria, 
were 1.93 (1.01 to 3.69) for microalbuminuria and 3.60 (1.09 to 
11.85) for macroalbuminuria. The corresponding OR (95% CI) 
for low GFR was 1.18 (0.54 to 2.55).
In the analysis classifying life time former smokers by their 
smoking duration, the adjusted OR (95% CI) for former smok-
ers who smoked <20 years, former smokers who smoked ≥ 
20 years, and current smokers were 1.15 (0.58 to 2.28), 1.54 
(0.85 to 2.80) and 2.42 (1.33 to 4.39), respectively (Supplemen-
tal Table 1). 
Table 2. Characteristics of 629 male patients with diabetes by presence of diabetic nephropathy, albuminuria and low GFR
Variables
Diabetic nephropathy 
(albuminuria1 or low GFR2) Albuminuria Low GFR
Normal
(n=416)
Diabetic 
nephropathy
(n=213)
p-value Normal(n =  455)
Albuminuria
(n =  174) p-value
Normal
(n =  551)
Low GFR
(n =  78) p-value
Age (y) 61.0±10.5 65.6±9.5 <0.001 61.6±10.6 64.9 ± 9.6 <0.001 61.8±10.3 67.8±9.5 <0.001
Duration of diabetes (y) 8.3±8.1 10.7±9.1 0.001 8.4±8.3 11.0 ± 8.9 0.001 8.8±8.2 11.6±10.4 0.02
BMI (kg/m2) 24.3±2.9 24.3±3.1 0.99 24.3±2.9 24.3 ± 3.2 0.94 24.3±3.0 24.2±2.8 0.85
SBP (10 mmHg) 123.7±15.9 130.8±20.5 <0.001 123.6±15.6 132.6 ± 21.4 <0.001 126.0±17.8 126.6±18.7 0.81
HbA1c (%)
  <7.0 197 (47.4) 78 (36.6) 0.01 218 (47.9) 57 (32.8) 0.001 238 (43.2) 37 (47.4) 0.56
  ≥7.0 219 (52.6) 135 (63.4) 237 (52.1) 117 (67.2) 313 (56.8) 41 (52.6)
Medication for hypertension
  No 237 (57.0) 84 (39.4) <0.001 253 (55.6) 68 (39.1) <  0.001 295 (53.5) 26 (33.3) 0.001
  Yes 179 (43.0) 129 (60.6) 202 (44.4) 106 (60.9) 256 (46.5) 52 (66.7)
Dyslipidemia3
  No 245 (58.9) 117 (54.9) 0.39 271 (59.6) 91 (52.3) 0.12 314 (57.0) 48 (61.5) 0.52
  Yes 171 (41.1) 96 (45.1) 184 (40.4) 83 (47.7) 237 (43.0) 30 (38.5)
Smoking behavior after diagnosis of diabetes
  Never smoked 67 (16.1) 23 (10.8) 0.009 71 (15.6) 19 (10.9) 0.002 80 (14.5) 10 (12.8) 0.76
  Smoked only 
   before diagnosis
   of diabetes
156 (37.5) 69 (32.4) 176 (38.7) 49 (28.2) 193 (35.0) 32 (41.0)
  Ever smoked 
   after diagnosis 
   of diabetes
193 (46.4) 121 (56.8) 208 (45.7) 106 (60.9) 278 (50.5) 36 (46.2)
Values are presented as mean±standard deviation or number (%). 
GFR, glomerular filtration rate; BMI, body mass index; SBP, systolic blood pressure; HbA1c, hemoglobin A1c.
1Albuminuria is defined as spot urine albumin/creatinine ratio ≥30 mg/g.
2Low GFR is defined as estimated glomerular filtration rate <60 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease formula.
3Dyslipidemia includes those with total cholesterol ≥200 mg/dL, or triglyceride ≥150 mg/dL, or medication for dyslipidemia.
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Table 3. Association between smoking behavior after diagnosis of diabetes and presence of diabetic nephropathy among pa-
tients with diabetes
Variables Total Diabetic nephropathy1 Unadjusted Adjusted2
Age (10 y) 629 213 (33.9) 1.60 (1.34, 1.91) 1.62 (1.31, 2.02)
Duration of diabetes (10 y) 1.38 (1.14, 1.67) 1.13 (0.91, 1.41)
Hemoglobin A1c (%) 1.16 (1.04, 1.30) 1.21 (1.07, 1.38)
Body mass index (kg/m2) 1.00 (0.95, 1.06) 1.03 (0.97, 1.10)
Systolic blood pressure (10 mmHg) 1.25 (1.14, 1.38) 1.22 (1.10, 1.35)
Medication for hypertension
   No 321 84 (26.2) 1.00 (reference) 1.00 (reference)
   Yes 308 129 (41.9) 2.03 (1.45, 2.85) 1.40 (0.95, 2.06)
Dyslipidemia3
  No 362 117 (32.3) 1.00 (reference) 1.00 (reference)
  Yes 267 96 (36.0) 1.18 (0.84, 1.64) 1.05 (0.72, 1.53)
Smoking behavior
  Never smoked 90 23 (25.6) 1.00 (reference) 1.00 (reference)
  Smoked only before diagnosis of diabetes 225 69 (30.7) 1.29 (0.74, 2.24) 1.23 (0.68, 2.21)
  Ever smoked after diagnosis of diabetes 314 121 (38.5) 1.83 (1.08, 3.09) 2.12 (1.20, 3.73)
Values are presented as number (%) or odds ratio (95% confidence interval). 
1Diabetic nephropathy is defined as spot urine albumin/creatinine ratio ≥30 mg/g or estimated glomerular filtration rate <60 mL/min/1.73 m2.
2Adjusted for other variables in the table (age, duration of diabetes, hemoglobin A1c, body mass index, systolic blood pressure, medication for hypertension, 
dyslipidemia, and smoking behavior).
3Dyslipidemia includes total cholesterol ≥200 mg/dL, or triglyceride ≥150 mg/dL, or taking medication for dyslipidemia.
Table 4. The association between smoking and presence of albuminuria and low glomerular filtration rate
Variables Total
Urine albumin/creatinine ratio1 Glomerular filtration rate2
30 - 299 mg/g ≥300 mg/g <60 mL/min/1.73 m2
Smoking behavior
   Never smoked 90 15 (16.7)  1.00 (reference)  4 (4.4)   1.00 (reference) 10 (11.1)  1.00 (reference)
   Smoked only before diagnosis of diabetes 225 40 (17.8)  0.99 (0.50, 1.98)  9 (4.0)   1.28 (0.34, 4.75) 32 (14.2)  1.34 (0.61, 2.96)
   Ever smoked after diagnosis of diabetes 314 73 (23.3)  1.93 (1.01, 3.69)  33 (10.5)   3.60 (1.09, 11.85) 36 (11.5)  1.18 (0.54, 2.55)
Values are presented as number (%) or odds ratio (95% confidence interval). 
Each model was adjusted for age, duration of diabetes, hemoglobin A1c, body mass index, systolic blood pressure, medication for hypertension, and dyslipid-
emia. Dyslipidemia includes those with total cholesterol ≥200 mg/dL, or triglyceride ≥150 mg/dL, or medication for dyslipidemia.
1The reference group for multivariate logistic regression is urine albumin/creatinine ratio <30 mg/g.
2The reference group for multiple logistic regression is glomerular filtration rate ≥60 mL/min/1.73 m2.
DISCUSSION
In this study we evaluated the association between smoking 
behavior and the presence of diabetic nephropathy, classify-
ing smoking behavior relative to the date of diabetes diagno-
sis. Cigarette smoking, especially smoking that continued after 
a diagnosis of diabetes was independently associated with the 
presence of diabetic nephropathy.
In the literature, smoking was related with adverse out-
comes on glomerular structure and function for patients with 
diabetes. Compared with nonsmoking patients with diabetes, 
smoking patients with diabetes had higher albumin excretion 
rates and thicker glomerular basement membranes [19]. The 
incidence or progression rate of diabetic nephropathy was 
higher in smokers than non-smokers [9,10]. In these studies 
the risk of nephropathy was highest for current smokers, fol-
lowed by former smokers and non-smokers. This finding sug-
gests that smoking, particularly continuous smoking, is associ-
ated with diabetic nephropathy.
Smoking also increases the risk of albuminuria or renal dys-
function in the non-diabetic population. According to some 
cross-sectional studies of non-diabetic persons, smoking was 
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related with the presence of albuminuria or low GFR [14,20]. 
Smoking was also associated with increased prevalence of 
proteinuria in repeated health screening examinations [21]. In 
some of these studies, daily amounts of smoking showed a 
dose-response relationship with albuminuria [14,21]. Smoking 
exposure seems to be related with diabetic nephropathy, re-
gardless of the point in time that the exposure occurred, be-
fore or after the onset of diabetes. In our results, the OR for 
former smokers who smoked only before diagnosis of diabe-
tes was higher than for non-smokers but lower than for smok-
ers who smoked at any time after receiving their diagnosis of 
diabetes. Therefore we conclude that smoking exposure, espe-
cially when diabetes is prevalent, is associated with diabetic 
nephropathy.
Some studies have suggested that smoking cessation can 
delay the progression of diabetic nephropathy. Lower progres-
sion to diabetic nephropathy or improvement of the ACR in 
former smokers had been observed in prospective studies of 
diabetic subjects who exhibited microalbuminuria [12,13,22]. 
It has been reported that total smoking pack-years showed a 
dose response relationship with the prevalence of diabetic ne-
phropathy among former smokers [9,23]. A prospective study 
that focused on the relationship of smoking pack-years and 
the incidence of diabetes showed a similar result. In this study, 
the hazard of diabetes was higher as smoking pack-years in-
creased and when the time since smoking cessation was 
shorter [24]. This dose-response relationship was partially 
shown in our analysis. When we stratified former smokers by 
smoking duration, the OR was higher for the group formed of 
those who smoked for longer periods of time. We could not 
expand the analysis to include subjects identified as current 
smokers in KNHANES, due to incomplete smoking duration in-
formation in the survey. We also considered the association of 
time between smoking cessation and diabetes diagnosis with 
the presence of diabetic nephropathy among former smokers 
(data not shown). The regression indicated a higher OR when 
the time interval was shorter, but the result was not statistical-
ly significant. To more fully reveal the effect of smoking, fur-
ther prospective studies evaluating smoking in conjunction 
with diabetes and with diabetic complications will be required.
The pathogenesis of diabetic nephropathy from diabetes 
stems from high blood glucose and blood lipid levels. High 
blood glucose and lipids increase oxidative stress and induce 
inflammation of renal structures [25,26]. Smoking is associat-
ed with high blood lipids, and independently increases oxida-
tive stress [27-29]. We assume that smoking participates in the 
development of diabetic nephropathy by mediating its pro-
gression along these pathways. Moreover, smokers take ac-
tions that exacerbate the impact of smoking. They have been 
shown to be unaware of the progression of a chronic disease, 
leading to low levels of treatment for that disease. Even when 
they are aware of disease, they, frequently, continue smoking. 
[30,31]. If the same pattern of behavior holds with diabetes, 
the delay in diagnosis and the delay in treatment increases the 
likelihood of complications. Microvascular complications may 
have already progressed by the time they receive a diagnosis 
of diabetes. If nothing else, delayed diagnosis and treatment 
results in prolonging the time in which the patient suffers in a 
hyperglycemic state [32]. Based on the literature and our find-
ings, we conclude that smoking is independently associated 
with diabetic nephropathy, and that the impact is higher 
when diabetes is prevalent. We also cautiously interpret the 
literature and our findings to indicate that smoking cessation 
in patients with diabetes may delay the progression of diabet-
ic nephropathy or slow the decrease of glomerular function.
When we grouped subjects separately by albuminuria and 
then by low GFR, rather than by diabetic nephropathy, we 
found that the prevalence of albuminuria was significantly 
higher among those that smoked at any point in time after di-
agnosis of diabetes. This finding was consistent with many 
other studies which evaluated smoking and albuminuria 
[8,20]. The distribution of smoking behavior, however, was not 
significantly different for those with normal and low GFR in 
our results. We do not know the exact reason for this, but 
some studies have reported that smoking can be related to ei-
ther decreased or increased GFR [14,33]. They explained that 
smoking acutely induces a decrease in renal plasma flow, but 
that these repeated episodes alter the structure of glomerular 
vessels and result in hyperfiltration [14,34]. We assume that 
these conflicting effects of smoking over time have been 
mixed in our cross-sectional analysis.
There are several limitations to our study. First, we could not 
establish causal relationships between smoking behavior and 
diabetic nephropathy due to the cross-sectional study design. 
We could not determine whether smoking was associated 
with the early development or progression of diabetic ne-
phropathy. Second, participation in the KNHANES was limited 
to non-institutionalized, community-dwelling individuals [35]. 
This may have led to the exclusion of patients with diabetes 
and advanced stages of diabetic nephropathy. Moreover, our 
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study excluded female participants, and so, its results cannot 
be generalized to the entire diabetic population. Third, our 
study was limited to those diagnosed with diabetes by a phy-
sician. We required the diagnosis date. The 2011-2013 
KNHANES surveys included 755 subjects who were undiag-
nosed but satisfied the diagnostic criteria for diabetes (fasting 
blood glucose ≥126 mg/dL or HbA1c ≥6.5%) based on 
blood tests [36]. While these individuals were not included in 
our study, we confirmed that they exhibited smoking behavior 
similar to that of our subjects. Therefore, we assume that the 
results of a study that included these undiagnosed individuals 
would be consistent with the results of this current study. 
Fourth, we used the date of diagnosis rather than diabetes on-
set in our study. In some cases diabetes could have been pres-
ent for many years before diagnosis and diabetic nephropathy 
could have been present when diabetes was diagnosed [4]. 
However, the date of diagnosis still has a clinical implication. It 
may have been used to persuade diabetic smokers to quit. 
Fifth, the effect of covariates might not be well controlled. 
There were confounding factors which we could not include. 
KNHANES 2013 lacked information needed to estimate smok-
ing duration for current smokers, and the 2011 and 2012 sur-
veys did not ask participants about their daily tobacco con-
sumption. In addition, we had incomplete data regarding in-
sulin resistance. Serum insulin was not measured in KNHANES 
after 2011 [22]. Finally, our study did not clearly distinguish 
between type 1 diabetes and type 2 diabetes. We do know, 
however, that the proportion of diabetics with type 1 diabetes 
is small in Korea [37].
In conclusion, smoking after a diagnosis of diabetes is asso-
ciated with the presence of diabetic nephropathy. Prospective 
research studies, evaluating the effect of smoking on diabetic 
nephropathy are required.
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Supplemental Table 1. The association between smoking behavior and duration, and presence of diabetic nephropathy
Variables Total Diabetic nephropathy1 Unadjusted  Adjusted2
Smoking behavior
   Non-smoker 90 23 (25.6) 1.00 (reference) 1.00 (reference)
   Former smoker: smoking duration (y)
      <20 102 30 (29.4) 1.21 (0.64, 2.29) 1.15 (0.58, 2.28)
      ≥20 205 74 (36.1) 1.65 (0.95, 2.86) 1.54 (0.85, 2.80)
   Current smoker 225 85 (37.8) 1.77 (1.03, 3.05) 2.42 (1.33, 4.39)
Values are presented as number (%) or odds ratio (95% confidence interval). Total 7 subjects were further excluded in this analysis due to the lack of smoking duration.
1Diabetic nephropathy is defined as spot urine albumin/creatinine ratio ≥30 mg/g or estimated glomerular filtration rate <60 mL/min/1.73 m2 according to the 
Modification of Diet in Renal Disease formula.
2Adjusted for age, duration of diabetes, hemoglobin A1c, body mass index, systolic blood pressure, medication for hypertension, and dyslipidemia. Dyslipidemia 
includes those with total cholesterol ≥200 mg/dL, or triglyceride ≥150 mg/dL, or medication for dyslipidemia.
